利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

158 条记录 (耗时 0.049 秒)

    A chronic renal disease diagnostic kit
    2.
    发明申请
    A chronic renal disease diagnostic kit 审中-公开

    公开(公告)号：US20170184593A1

    公开(公告)日：2017-06-29

    申请号：US15300236

    申请日：2015-12-18

    申请人： WENZHOU MEDICAL UNIVERSITY

    发明人： Xiaokun Li ,  Guang Liang ,  Xiaojie Wang ,  Shijun Li ,  Peisheng Hu

    IPC分类号： G01N33/577

    CPC分类号： G01N33/577 ,  G01N33/6872 ,  G01N2333/50 ,  G01N2800/347

    摘要： This invention publicizes a chronic renal disease diagnostic kit, comprised of FGF23 monoclonal antibody, biotin labeling reagent Sulfo-NHS-LC-Biotin, PBS buffer solution (pH7.0, 0.1M), casein saline solution, streptomycin avidin and substrate TMB. The labeling condition is the weight ratio of FGF23 antibody and Sulfo-NHS-LC-Biotin, which is 1:5-1:12. The dilution ratio of streptomycin avidin is 1:3000. The lowest testing threshold limit value of FGF23 kit is 10 pg/ml, whose sensitivity is 10 times higher than that of common monoclonal antibody, which is very significant for early diagnose of chronic renal disease.

    CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE
    4.
    发明申请
    CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE 审中-公开
    CHIMERIC FIBROBLAST GROWTH FACTOR 21蛋白质和使用方法

    公开(公告)号：US20170029480A1

    公开(公告)日：2017-02-02

    申请号：US15289447

    申请日：2016-10-10

    申请人： New York University

    发明人： Moosa MOHAMMADI ,  Regina GOETZ

    IPC分类号： C07K14/50 ,  A61K45/06 ,  A61K38/18

    CPC分类号： C07K14/50 ,  A61K31/00 ,  A61K38/1825 ,  A61K45/06 ,  C07K14/501 ,  C07K14/503 ,  C07K2319/00 ,  G01N2333/50 ,  G01N2500/02 ,  G01N2800/042 ,  A61K2300/00

    摘要： The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.

    摘要翻译： 本发明涉及包含与C-末端偶联的N-末端的嵌合蛋白，其中N末端包括一部分旁分泌成纤维细胞生长因子（“FGF”），并且C-末端包括C末端 部分FGF21分子。 与没有修饰的部分相比，旁分泌FGF的部分被修饰以降低对肝素和/或硫酸乙酰肝素的结合亲和力。 本发明还涉及包含根据本发明的嵌合蛋白质的药物组合物，用于治疗患有糖尿病，肥胖或代谢综合征的受试者的方法，以及筛选具有增强的对βKlotho-FGF受体复合物的结合亲和力的化合物的方法，涉及 使用本发明的嵌合蛋白。

    Immunoassays and methods of detecting and measuring intact fibroblast growth factor 23, and C-terminal and N-terminal fragments thereof
    6.
    发明授权
    Immunoassays and methods of detecting and measuring intact fibroblast growth factor 23, and C-terminal and N-terminal fragments thereof 有权
    检测和测量完整成纤维细胞生长因子23的免疫测定和方法及其C-末端和N-末端片段

    公开(公告)号：US09377473B2

    公开(公告)日：2016-06-28

    申请号：US13841800

    申请日：2013-03-15

    申请人： Harald Jueppner

    发明人： Jeffrey Lavigne ,  Richard Zahradnik

    IPC分类号： G01N33/00 ,  G01N33/74

    CPC分类号： G01N33/74 ,  G01N2333/50

    摘要： Immunoassays and methods for detecting and quantifying biological levels of intact fibroblast growth factor (FGF)-23, as well as the N-terminal and C-terminal fragments thereof in a biological sample. The relative amounts or ratios of FGF-23 relative the N-terminal and C-terminal fragments can also be determined. The systems and methods deploy antibodies that are specific to antigenic regions formed upon either the N-terminal or C-terminal regions of FGF-23 and are systematically applied such that intact FGF-23 and the fragments thereof can be detected and quantified. In certain embodiments, dissimilar labels conjugated to tracer antibodies or labeled antibodies specific to N-terminal and/or C-terminal tracer antibodies are utilized to facilitate detection and quantification of both whole length FGF-23 and any fragments thereof.

    摘要翻译： 用于检测和定量完整成纤维细胞生长因子（FGF）-23的生物学水平的免疫测定和方法，以及生物样品中的N-末端和C-末端片段。 也可以确定FGF-23相对于N-末端和C-末端片段的相对量或比例。 系统和方法部署了对FGF-23的N末端或C末端区域上形成的抗原区域特异性的抗体，并被系统地应用，从而可以检测和定量完整的FGF-23及其片段。 在某些实施方案中，使用与示踪抗体缀合的不同标记或对N-末端和/或C-末端示踪抗体特异性的标记抗体来促进全长FGF-23及其任何片段的检测和定量。

    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING
    8.
    发明申请
    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 审中-公开
    鉴别患有异常分娩的患者

    公开(公告)号：US20150185230A1

    公开(公告)日：2015-07-02

    申请号：US14644695

    申请日：2015-03-11

    申请人： Roche Diagnostics Operations, Inc

    发明人： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC分类号： G01N33/68 ,  A61B5/055 ,  A61B8/08

    CPC分类号： G01N33/6887 ,  A61B5/055 ,  A61B8/0883 ,  G01N33/82 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/4712 ,  G01N2333/50 ,  G01N2333/78 ,  G01N2800/32 ,  G01N2800/329 ,  G01N2800/50

    摘要： The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

    摘要翻译： 本发明涉及一种用于评估受试者是否应进行基于成像的诊断评估的方法。 该方法基于来自受试者的样品中心肌肌钙蛋白和/或成纤维细胞生长因子23（FGF-23）的量的测定，以及因此确定的量（s） 具有参考量（参考量）。 本发明还涉及一种用于执行评估受试者是否应进行基于成像的诊断评估的系统以及用于执行本文所公开的方法的试剂和试剂盒。 此外，本发明涉及一种用于预测死亡风险和/或心血管事件风险的方法。 还包括用于诊断具有保留的左心室射血的受试者的LVH的早期阶段的方法。

    Methods useful for vitamin D deficiency and related disorders
    9.
    发明授权
    Methods useful for vitamin D deficiency and related disorders 有权
    对维生素D缺乏症及相关疾病有用的方法

    公开(公告)号：US08962239B2

    公开(公告)日：2015-02-24

    申请号：US12935139

    申请日：2009-04-02

    申请人： P. Martin Petkovich ,  Christian F. Helvig ,  Joel Z. Melnick

    发明人： P. Martin Petkovich ,  Christian F. Helvig ,  Joel Z. Melnick

    IPC分类号： C12Q1/68 ,  G01N33/53 ,  G01N33/573 ,  A01N45/00 ,  A61K31/00 ,  A61K45/06 ,  G01N33/68

    CPC分类号： G01N33/82 ,  A61K31/00 ,  A61K31/59 ,  A61K31/592 ,  A61K31/593 ,  A61K45/06 ,  C12Q1/6876 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/50 ,  G01N2333/90251 ,  G01N2800/04 ,  G01N2800/046 ,  G01N2800/347

    摘要： Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.

    摘要翻译： 公开了用于诊断，治疗和预防分解代谢相关的维生素D缺乏症和相关疾病的方法，相关组合物，装置和试剂盒。 一种方法包括测量患者中的CYP24表达和/或活性或其代谢如FGF23水平，并将与异常升高的CYP24表达和/或活性与分解代谢相关的维生素D缺乏或与分解代谢相关的维生素D缺乏的易感性相关联 。 响应于异常升高的CYP24表达和/或活性，该方法还包括向维生素D缺乏或危险患者施用CYP24抑制剂，并且优选地避免维生素D结合受体的活化，例如通过避免施用活性维生素 D化合物。 任选地，可以施用维生素D激素原或激素原。